PT - JOURNAL ARTICLE AU - Lightowler, Maria S. AU - Manangazira, Portia AU - Nackers, Fabienne AU - Van Herp, Michel AU - Phiri, Isaac AU - Kuwenyi, Kuziwa AU - Panunzi, Isabella AU - Garone, Daniela AU - Marume, Farayi AU - Tarupiwa, Andrew AU - Ferreras, Eva AU - Duri, Clemence AU - Luquero, Francisco J. TI - Effectiveness of Typhoid Conjugate Vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study AID - 10.1101/2022.03.28.22273032 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.28.22273032 4099 - http://medrxiv.org/content/early/2022/03/31/2022.03.28.22273032.short 4100 - http://medrxiv.org/content/early/2022/03/31/2022.03.28.22273032.full AB - Background Zimbabwe suffers from regular outbreaks of typhoid fever (TF), worse since 2017. Most cases were in Harare and a vaccination campaign with Typhoid Conjugate Vaccine (TCV) was conducted in March 2019. The vaccine effectiveness (VE) was assessed against culture-confirmed S. Typhi in children six months to 15 years and in individuals six months to 45 years in Harare.Methods A matched case-control study was conducted in three urban suburbs of Harare targeted by the TCV vaccination campaign. Suspected TF cases were enrolled prospectively in four health facilities and were matched to facility (1:1) and community (1:5) controls.Findings Of 504 suspected cases from July 2019 to March 2020, 148 laboratory-confirmed TF cases and 153 controls confirmed-negative were identified. One hundred and five (47 aged six months to 15 years) cases were age, sex, and residence matched with 105 facility-based controls while 96 cases were matched 1:5 by age, sex, and immediate-neighbour with 229 community controls.The adjusted VE against confirmed TF was 75% (95%CI: 1–94, p=0.049) compared to facility controls, and 84% (95%CI: 57–94, p<0.001) compared to community controls in individuals six months to 15 years. The adjusted VE against confirmed TF was 46% (95%CI: 26–77, p=0.153) compared to facility controls, and 67% (95%CI: 35–83, p=0.002) compared to community controls six months to 45 years old.Interpretation This study confirms that one vaccine dose of TCV is effective to control TF in children between six months and 15 years old in an African setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by Medecins Sans FrontieresAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Medical Research Zimbabwe Committee (approval number MRCZ/A/2460) and by the Medecins Sans Frontieres Ethics Review Board (approval number 18114).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual pseudonymised participant data that underlie the results reported in this article (text, tables, figures, and appendices, with data dictionary) will be made available to others upon submission of a proposal. Requests will be reviewed and sharing of the data will follow the conditions required by all applicable laws and the possible prior signature of any necessary agreement, in accordance with the legal framework set forth by Medecins Sans Frontieres (MSF) data sharing policy, which ensures that all security, legal, and ethical concerns are addressed.